Developing new drugs for the treatment of lymphoma

European Journal of Haematology, Supplement

Volumn 75, Issue 66, 2005, Pages 150-158

  O'Connor, Owen A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bortezomib; Histone deacetylase inhibitor; Lymphoma; PDX; Proteasome inhibitor; Suberoylanilide hydroxamic acid

Indexed keywords

10 PROPARGYL 10 DEAZAAMINOPTERIN; ANTHRAQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; BORTEZOMIB; CYTARABINE; CYTIDINE DERIVATIVE; DEPSIPEPTIDE; DOXORUBICIN; FOLIC ACID ANTAGONIST; FR 901228; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN; METHOTREXATE; MONOCLONAL ANTIBODY; NEW DRUG; PHENYLACETIC ACID; PROTEASOME INHIBITOR; PROTEIN BCL 2; UNCLASSIFIED DRUG; VALPROIC ACID; VINCRISTINE; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; DEHYDRATION; DIARRHEA; DRUG FORMULATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; EMPIRICISM; GASTROINTESTINAL TOXICITY; HODGKIN DISEASE; HUMAN; LYMPHOMA; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; SKIN TOXICITY; T CELL LYMPHOMA; THROMBOCYTOPENIA; TOXICITY; TREATMENT OUTCOME;

EID: 84900429883     PISSN: 09024506     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2005.00470.x     Document Type: Conference Paper

References (41)

1. HERSHKO A, CIECHANOVER A, ROSE IA. Resolution of the ATP-dependent proteolytic system from reticulocytes: a component that interacts with ATP. Proc Natl Acad Sci USA 1979;76:3107-3110.
2. CIECHANOVER A, HELLER H, ELIAS S, et al. ATP-dependent conjugation of reticulocyte proteins with the polypeptide required for protein degradation. Proc Natl Acad Sci USA 1980;77:1365-1368.
3. HERSHKO A, CIECHANOVER A, HELLER H, et al. Proposed role of ATP in protein breakdown: conjugation of protein with multiple chains of the polypeptide of ATP-dependent proteolysis. Proc Natl Acad Sci USA 1980;77: 1783-1786.
4. CIECHANOVER A, ELIAS S, HELLER H, et al. Characterization of the heat-stable polypeptide of the ATP-dependent proteolytic system from reticulocytes. J Biol Chem 1980;255:7525-7528.
5. CIECHANOVER A, HELLER H, KATZ-ETZION R, et al. Activation of the heat-stable polypeptide of the ATP-dependent proteolytic system. Proc Natl Acad Sci USA 1981;78:761-765.
6. HERSHKO A, CIECHANOVER A, ROSE IA. Identification of the active amino acid residue of the polypeptide of ATP-dependent protein breakdown. J Biol Chem 1981;256:1525-1528.
7. CIECHANOVER A. The ubiquitin-proteasome proteolytic pathway. Cell 1994;79:13-21.
8. PALOMBELLA VJ, CONNER EM, FUSELER JW, et al. Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA 1998;95:15671-15676.
9. SIEBENLIST U, FRANZOSO G, BROWN K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol 1994;10:405-55.
10. BALDWIN AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-683.
11. HINZ M, LOSER P, MATHAS S, et al. Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood 2001; 97:2798-2807.
12. SIEBENLIST U, FRANZOSO G, BROWN K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol 1994;10:405-455.
13. VASKIVUO TE, STENBACK F, TAPANAINEN JS. Apoptosis and apoptosis-related factors Bcl-2, Bax, tumor necrosis factor-alpha, and NF-kappaB in human endometrial hyperplasia and carcinoma. Cancer 2002;95:1463-1471.
14. MARSHANSKY V, WANG X, BERTRAND R, et al. Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells. J Immunol 2001;166:3130-3142.
15. YOUNES A, PRO B, ROMAGNERA J, DANG N. Safety and efficacy of bortezomib (Velcade) for the treatment of relapsed classical Hodgkin's disease. Am Soc Hematol 2004;104:(Abstract 2638).
16. O'CONNOR OA, WRIGHT J, MOSKOWITZ C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676-84.
17. O'CONNOR O, WRIGHT J, MOSKOWITZ C, et al. A multicenter Experience with Single Agent Bortezomib in Non-Hodgkin's Lymphoma Reveals Marked Difference in Sub-Type Sensitivity to Proteasome Inhibition. Blood 2004;104: (Abstract 607).
18. GOY A. PHASE II study of bortezomib in relapsed/refractory B-cell NHL. J Clin Oncol 2005;23:667-676.
19. STRAUSS S, MAHARAJ L, STEC J. et al. PHASE II clinical study of bortezomib (VELCADE) in patients (pts) with relapsed/refractoryy non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). Blood 2004; 104: (Abstract 1386).
20. BELCH A, KOUROUKIS T, CRUMP M et al. PHASE II trial of bortezomib in mantle cell lymphoma. Blood 2004; 104: (Abstract 608).
21. MARKS PA, RICHON VM, RIFKIND RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92:1210-1216.
22. KELLY WK, O'CONNOR OA, MARKS PA. Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Investig Drugs 2002;11:1695-1713.
23. KELLY WK, RICHON VM, O'CONNOR O, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003;9:3578-3588.
24. RICHON VM, EMILIANI S, VERDIN E, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 1998;95:3003-3007.
25. BUTLER LM, AGUS DB, SCHER HI, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000;60:5165-5170.
26. STRUHL K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 1998;12:599-606.
27. FINNIN MS, DONIGIAN JR, COHEN A, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999;401:188-193.
28. GRUNSTEIN M. Histone acetylation and chromatin sturcture and transcription. Nature 1997;389:349-352.
29. TURNER B. Decoding nucleosome. Cell 1993;75:5-8.
30. PIEKARZ RL, ROBEY R, SANDOR V, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001;98:2865-2868.
31. PIEKARZ RL, FRYE R, ZHAN Z, TURNER M, ROBEY R, STEADMAN K, FOJO T, BATES S. Depsipeptide (FK228) in patients with cutaneous t cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy. Blood 2003;102: (Abstract 2366).
32. DUVIC M, TALPUR R, CHIAO R, Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). Blood 2003;102: (Abstract 625).
33. SWEET DL, GOLOMB HM, ULTMANN JE, et al. Cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (COMLA) combination sequential chemotherapy for advanced diffuse histiocytic lymphoma. Ann Intern Med 1980;92:785-790.
34. KHOURI IF, ROMAOUERA J, KANTARJIAN H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998;16:3803-3809.
35. PLANTIER-COLCHER I, DUPRIEZ B, SIMON M, et al. The VIM3-AraC regimen followed by autologous stem cell transplantation in refractory or relapsing aggressive non-Hodgkin's lymphoma. A prospective study of 71 consecutive cases. Leukemia 1999;13:282-288.
36. FISHER RI, GAYNOR ER, DAHLBERG S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-1006.
37. STAMATOULLAS A, FRUCHART C, BASTIT D, et al. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer 1996;77:2302-2307.
38. SIROTNAK FM, DEGRAW JI, CHELLO PL, et al. Biochemical and pharmacologic properties of a new folate analog, 10-deaza-aminopterin, in mice. Cancer Treat Rep 1982; 66:351-358.
39. WANG ES, O'CONNOR O, SHE Y, et al. Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma 2003;44:1027-1035.
40. SIROTNAK FM, DEURAW JI, MOCCIO DM, et al. New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties. Cancer Chemother Pharmacol 1984;12:18-25.
41. TONER LVR, SMITH E, GARDNER J, HEANEY M, TERUYA-FELDSTEIN J, SIROTNAK F, O'CONNOR O. The schedule dependent effects of the novel antifolate 10-propargyl-10dezaminopterin (PDX) and gemcitabine are markedly superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. Sumbitted.